DDInter1946 DDInter1676
Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms. Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Voriconazole {u} (Compound) binds {v} (Gene) CYP2B6
Voriconazole {u} (Compound) upregulates {v} (Gene) SELL
Voriconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Voriconazole {u} (Compound) causes {v} (Side Effect) Arthralgia
Voriconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Voriconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Voriconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Voriconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avatrombopag
Voriconazole {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Voriconazole {u} may lead to a major life threatening interaction when taken with {v} Acetohexamide
Voriconazole (Compound) binds CYP2B6 (Gene)
Voriconazole (Compound) upregulates SELL (Gene)
Voriconazole (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Voriconazole (Compound) causes Arthralgia (Side Effect)
Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Voriconazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Voriconazole may lead to a major life threatening interaction when taken with Dasatinib
Voriconazole may lead to a major life threatening interaction when taken with Acetohexamide